A phase III clinical trial (NCT03980054) of extended adjuvant pyrotinib in patients with high-risk HER2-positive breast cancer is ongoing, which will further demonstrate the efficacy of extended adjuvant TKI and bring new hope for patients with high-risk HER2-positive breast cancer. Here, ERBB2 is linked to breast carcinoma.